Non–Small Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Non–Small Cell Lung Cancer (NSCLC) Market Outlook

Thelansis’s “Non–Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non–Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non–Small Cell Lung Cancer (NSCLC) Overview

Non-small cell lung cancer (NSCLC) is the predominant variant of lung cancer, comprising most cases. About 18% of these cases pertain to early-stage NSCLC, typically necessitating a multifaceted therapeutic approach to a potential cure. The origins of NSCLC can classified into two distinct categories: factors that could have been avoided and those that were unavoidable. Among the most renowned avoidable risk factors for NSCLC is the inhalation of tobacco, but other contributors encompass alcohol consumption, exposure to secondhand smoke, contact with hazardous substances like asbestos, radon, arsenic, chromium, and nickel, as well as exposure to ionizing radiation and polycyclic aromatic hydrocarbons. Radiation therapy in treating other malignancies, such as breast cancer and Hodgkin lymphoma can also induce primary lung cancer. The suspicion of NSCLC diagnosis typically arises when a patient presents with intrathoracic symptoms and is subsequently found to have a pulmonary nodule on a chest radiograph. Given these intrathoracic symptoms and potential chest radiograph findings, the differential diagnosis encompasses a spectrum of possibilities, including bronchogenic carcinoma (such as adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and small cell carcinoma), metastatic disease from various primary sites, pulmonary carcinoid, extranodal lymphoma, and plasmacytoma or schwannoma. The complications arising from NSCLC are contingent upon the local extent of the disease and the potential involvement of metastases. Intrathoracic complications may manifest as malignant pleural effusion, resulting in dyspnea or respiratory failure, contingent on the pathology's extent and the presence of comorbid conditions. Additionally, non-small cell lung cancer is the predominant malignant cause of superior vena cava (SVC) syndrome, accounting for approximately 50% of all cases. The 5-year overall survival (OS) rate varies from 50% for stage IA disease to 15% for stage IIIA NSCLC. The established treatment approach for patients with stage I and II, as well as IIIA NSCLC, involves surgical resection. Post-resection, patients may be offered adjuvant systemic therapy.

• In the United States, NSCLC represents the predominant form of lung cancer, making up 81% of all lung cancer diagnoses.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: